Anticoagulant threpy for patients with obstetric antiphospholipid syndrome.

JRCT ID: jRCTs041180093

Registered date:13/03/2019

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Antiphospholipid syndrome
• Date of first enrollment: 13/01/2006
• Target sample size: 200
• Study type: Interventional

Intervention(s)

Trial: low dose aspirin (81-100mg)+Orgaran 1250U/day
control: low dose aspirin (81-100mg)+heparin calcium 5000Uxtwice/day

Outcome(s)

• Primary Outcome: Live birth rate
• Secondary Outcome: The frequency of heparin-induced thrombocytopenia, osteoporosis, liver dysfunction

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Female

Include criteria

Two or more early miscarriage
One or more fetal death
Preterm birth <34 weeks' gestation caused by preeclampsia or placental dysfunction
Antiphospholipid antibodies continue positive for 12 weeks.

Exclude criteria

abnormal chromosome in either partner
uterine anomaly
bleeding disease, renal dysfunction, liver dysfunction

Related Information

• Primary Sponsor: Sugiura Mayumi
• Secondary ID(s): UMIN000031012